• Login
    • Advanced search
    • Title
    • Channel
    • Module
  • Home
  • Industry
    •  

      • Aerospace, Defense, and Government Services
      • Automotive
      • Consumer
      • Manufacturing and Industrials
      • Education
      • Energy and Natural Resources
      • Financial Institutions
    •  

      • Insurance
      • Life Sciences and Health Care
      • Private Capital
      • Real Estate
      • Sports, Media and Entertainment
      • Technology and Telecoms
      • Transport and Logistics
  • Practice
    • Corporate & Finance

      • Banking and Loan Finance
      • Business Restructuring and Insolvency
      • Capital Markets
      • Corporate Governance and Public Company Representation
      • Digital Assets and Blockchain
      • Infrastructure, Energy, Resources, and Projects
      • Leveraged and Acquisition Finance
      • Mergers and Acquisitions
      • Pensions
      • Private Equity, Venture Capital and Investment Funds
      • Real Estate
      • Real Estate Investment Trusts (REITs)
      • Tax
      • Transfer Pricing
    • Global Regulatory

      • Administrative and Public Law
      • Antitrust and Competition
      • Communications, Internet, and Media
      • Education
      • Energy Regulatory
      • Environment and Natural Resources
      • Financial Services
      • Food Law
      • Gaming Law
      • Government Contracts and Public Procurement
      • Government Relations and Public Affairs
      • Health
      • Immigration
      • International Trade and Investment
      • Medical Device and Technology Regulatory
      • New Nuclear
      • Pharmaceuticals and Biotechnology Regulatory
      • Privacy and Cybersecurity
      • Space and Satellite
      • Strategic Operations, Agreements and Regulation
      • Transportation Regulatory
    • Intellectual Property

      • Copyright
      • Designs
      • Domain Names
      • IP and Technology Transactions
      • IP Enforcement
      • Patents
      • Trade Secrets and Confidential Know-how
      • Trademarks and Brands
      • Unfair Competition
    • Litigation, Arbitration, and Employment

      • Business and Human Rights
      • Construction and Engineering
      • Corporate and Securities Litigation
      • Employment
      • International Arbitration
      • Investigations, White Collar, and Fraud
      • Products Law
      • Risks, Disputes, and Litigation
  • Comparative guides
  • Engage Premium
  • Login
  • Register
Hogan Lovells Engage 5.7.13
      • Title
      • Channel
      • Module
    • Hit ENTER to search in content
    • Advanced search
    • Login
  • Home
  • Industry
    •  

      • Aerospace, Defense, and Government Services
      • Automotive
      • Consumer
      • Manufacturing and Industrials
      • Education
      • Energy and Natural Resources
      • Financial Institutions
    •  

      • Insurance
      • Life Sciences and Health Care
      • Private Capital
      • Real Estate
      • Sports, Media and Entertainment
      • Technology and Telecoms
      • Transport and Logistics
  • Practice
    • Corporate & Finance

      • Banking and Loan Finance
      • Business Restructuring and Insolvency
      • Capital Markets
      • Corporate Governance and Public Company Representation
      • Digital Assets and Blockchain
      • Infrastructure, Energy, Resources, and Projects
      • Leveraged and Acquisition Finance
      • Mergers and Acquisitions
      • Pensions
      • Private Equity, Venture Capital and Investment Funds
      • Real Estate
      • Real Estate Investment Trusts (REITs)
      • Tax
      • Transfer Pricing
    • Global Regulatory

      • Administrative and Public Law
      • Antitrust and Competition
      • Communications, Internet, and Media
      • Education
      • Energy Regulatory
      • Environment and Natural Resources
      • Financial Services
      • Food Law
      • Gaming Law
      • Government Contracts and Public Procurement
      • Government Relations and Public Affairs
      • Health
      • Immigration
      • International Trade and Investment
      • Medical Device and Technology Regulatory
      • New Nuclear
      • Pharmaceuticals and Biotechnology Regulatory
      • Privacy and Cybersecurity
      • Space and Satellite
      • Strategic Operations, Agreements and Regulation
      • Transportation Regulatory
    • Intellectual Property

      • Copyright
      • Designs
      • Domain Names
      • IP and Technology Transactions
      • IP Enforcement
      • Patents
      • Trade Secrets and Confidential Know-how
      • Trademarks and Brands
      • Unfair Competition
    • Litigation, Arbitration, and Employment

      • Business and Human Rights
      • Construction and Engineering
      • Corporate and Securities Litigation
      • Employment
      • International Arbitration
      • Investigations, White Collar, and Fraud
      • Products Law
      • Risks, Disputes, and Litigation
  • Comparative guides
  • Engage Premium
  • Login
  • Register
  1. News
  2. Safety first: MHRA response to UK medical device regulation consultation

Safety first: MHRA response to UK medical device regulation consultation

01 July 2022
    • Share by email
    • Share on
    • Twitter
    • LinkedIn
    • Get link
    • Get QR Code
    • Download
    • Print

The UK Medicines and Healthcare products Regulatory Agency (MHRA) has published its response to its consultation on the future regulation of medical devices in the United Kingdom which ran between September and November 2021.

Index
  1. Key takeaways
  2. Next steps and transitions

Medical devices and in vitro diagnostic medical devices in Great Britain are regulated under the Medical Devices Regulations 2002 (UK MDR). The UK MDR still reflects the historic EU medical devices directives, which have been replaced by the EU Medical Devices Regulation (2017/745) (EU MDR) and In Vitro Diagnostic Medical Devices Regulation (2017/746) (EU IVDR). 

The MHRA intends to reform the UK MDR following the UK’s exit from the EU to create an updated regulatory regime for medical devices and IVDs focusing on improved patient safety, transparency, alignment with international best practice, proportionality and facilitating new and emerging technologies.

In the response, the MHRA broadly confirms its intention to proceed with the proposals set out in the Consultation. These include that the updated UK MDR will be aligned with most of the key elements of the EU MDR and IVDR. However, the updated UK MDR will deviate from the EU regime in certain aspects and in some cases go beyond it, for instance in stricter standards for relying on "equivalence" of medical devices to use data from a different clinical investigation. Some divergence was expected as the UK begins to carve its own regulatory path.

Key takeaways

  • Scope: The scope of the regulation will expand, similar to the EU MDR, so that devices which currently fall outside the UK MDR but that operate similarly to and have the risk profile of a medical device are caught, e.g. dermal fillers and colour contact lenses.

  • Classification: There will be updates to the classification rules for medical devices, that again closely align with the EU MDR and EU IVDR and are intended to better reflect changing technologies.

  • Requirements: The current UK MDR “Essential Requirements” will be updated to broadly reflect the EU MDR and EU IVDR “General Safety and Performance Requirements”.

  • Software: Software will be defined and subject to separate requirements broadly in line with EU requirements, and follow the International Medical Device Regulators Forum (IMDRF) SaMD classification rule for general medical devices. No specific requirements for artificial intelligence as a medical device (AIaMD) will be introduced at this stage.

  • UKCA mark: While currently both CE and UKCA marked devices can be placed on the market, the UKCA mark will become mandatory.

  • Alternative routes to market: Both Medical Device Single Audit Program (MDSAP) certificates and an abridged assessment based on approvals from other countries,  “Domestic Assurance”, will be utilised as alternative routes to market in the UK.

  • Manufacturers’ obligations: Manufacturers will be required to have measures in place to provide recompense to those impacted by adverse incidents involving medical devices, such as sufficient financial coverage.

  • Traceability: There will be improved traceability of medical devices including requiring Unique Device Identifiers (UDIs) on every medical device, more comprehensive record keeping requirements and a new more comprehensive registration database.

The changes in the updated UK MDR are not limited to the above, with additional requirements relating to clinical investigations and performance studies, economic operators, UK Responsible Persons (UKRPs), Qualified Persons, quality management systems (QMS), conformity assessments, Approved Bodies, registration of devices, claims, distance sales and post-market surveillance also to be included.

Next steps and transitions

The MHRA still intends the updated UK MDR to come into force from 1 July 2023.

The response also gives the first confirmation of the intended transitional arrangements:

  • For devices that are UKCA marked before 1 July 2023, such products will be able to be placed on the GB market until 30 June 2026 (for medical devices) or 30 June 2028 (for IVDs) or until their certificate expires (whichever is sooner).
  • For devices CE marked under the previous EU medical devices directive before 1 July 2023, they can be placed on the GB market until 30 June 2026 (for medical devices) or 30 June  2028 (for IVDs) or until their certificate expires (whichever is sooner). 
  • Devices CE marked under the EU MDR or EU IVDR may continue to be placed on the GB market until 30 June 2028 or until their certificate expires (whichever is sooner). This will be effective even if the certification/declaration of conformity is dated after 1 July 2023.

Similar to the transitional arrangements under the EU MDR and EU IVDR, the transitional arrangements under the UK MDR are subject to conditions, including that they exclude devices subject to significant changes in design or intended purpose and devices will still be required to comply with all updated post-market requirements from 1 July 2023.

To meet the intended date of 1 July 2023, the next step will be for draft legislation implementing these changes to be published in the coming months.

 

 

Authored by Jane Summerfield and Bonella Ramsay.

Contacts
Jane Summerfield
Partner
London
Bonella Ramsay
Counsel
London
Index
  1. Key takeaways
  2. Next steps and transitions
Related Materials
Sanctions Navigator

Sanctions Navigator: Russia Sanctions

Keywords UK Medical Device Regulation, Medical Devices, MHRA Response, Regulatory, MDR IVDR
Languages English
Topics Life Science Government Enforcement and Compliance, Conformity Assessment Procedure/CE Mark, In Vitro Diagnostics, MDR/IVDR
Countries Belgium, France, Germany, Hungary, Italy, Luxembourg, Netherlands, Poland, Spain, United Kingdom
Delete Comment ?

Are you sure want to delete comment ?

Get link
Embed
Share by email
Get QR Code

Scan this QR Code to share this content

  • Contact us
  • Disclaimer
  • Privacy
  • Cookies
  • Legal Notices
  • Terms of Use

 

This website is operated by Hogan Lovells International LLP, whose registered office is at Atlantic House, Holborn Viaduct, London, EC1A 2FG. For further details of Hogan Lovells International LLP and the international legal practice that comprises Hogan Lovells International LLP, Hogan Lovells US LLP and their affiliated businesses ("Hogan Lovells"), please see our Legal Notices page. © 2022 Hogan Lovells.

Attorney advertising. Prior results do not guarantee a similar outcome.

Thomson Reuters HighQ Logo
© 2023 Hogan Lovells | Privacy Policy | Terms of Service